Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Long-Term Debt Repayments (2023 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $30.6 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Long-Term Debt Repayments changed N/A year-over-year to $30.6 million, compared with a TTM value of $49.6 million through Dec 2024, changed N/A, and an annual FY2024 reading of $49.6 million, down 0.9% over the prior year.
  • Long-Term Debt Repayments was $30.6 million for Q2 2024 at Oramed Pharmaceuticals, up from $19.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $30.6 million in Q2 2024 and bottomed at $19.0 million in Q1 2024.